Thyrocare Q1FY27 Revenue Up 24% to ₹240 Cr, PAT Up 34%
Thyrocare Technologies Ltd announced its unaudited financial results for the quarter ended June 30, 2027 (Q1FY27), reporting a consolidated revenue of ₹240.02 Cr, a 24% year-on-year increase. The company's Profit After Tax (PAT) surged by 34% YoY to ₹51.33 Cr, with EBITDA also growing 34% YoY to ₹77.27 Cr. This strong performance was driven by a 26% YoY growth in the Pathology segment, which saw franchise revenue increase by 27% and partnership revenue by 26%. Thyrocare processed 55.2 million tests, a 28% YoY growth, reinforcing its market leadership. The company also expanded into Specialty Diagnostics, including Allergy and Genomics, and maintained high-quality standards with reduced complaints and improved turnaround times.
Key Highlights
- Consolidated revenue grew 24% YoY to ₹240.02 Cr in Q1FY27.
- PAT increased 34% YoY to ₹51.33 Cr, EBITDA up 34% YoY to ₹77.27 Cr.
- Pathology segment revenue grew 26% YoY, with 55.2 million tests processed.
- Expanded into Specialty Diagnostics with Allergy and Genomics offerings.
- Reduced complaints by 24% YoY to 3.1 per million tests.
Price Impact
More from THYROCARE